"label","instanceType","uuid:ID","id","rationale","description","name"
"","StudyDesign","4b6f22f0-8f96-48fb-94ca-793fde437cc9","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1"
